Flex Pharma Reports First Quarter 2017 Financial Results -bit.ly/1M6Nxmj

Flex Pharma Presenting at Upcoming Investor Conferences in June 2017 - bit.ly/1M6Nxmj

Flex Pharma’s Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium - bit.ly/1M6Nxmj

Flex Pharma Announces Executive Leadership Transition -bit.ly/1M6Nxmj

HOTSHOT Partners With IRONMAN To Help Athletes Prevent Muscle Cramping prn.to/2skLytF

FDA Grants Fast Track Designation to Flex Pharma's FLX-787 for #ALS - bit.ly/1M6Nxmj

Flex Pharma to Report Second Quarter 2017 Results on August 2, 2017 - bit.ly/1M6Nxmj

Flex Pharma Names William McVicar President and Chief Executive Officer -bit.ly/1M6Nxmj

Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US - bit.ly/1M6Nxmj

Flex Pharma Reports Second Quarter 2017 Financial Results - bit.ly/1M6Nxmj

Flex Pharma Presenting at Upcoming Investor Conferences in September 2017 - bit.ly/1M6Nxmj

Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US - bit.ly/1M6Nxmj

Flex Pharma Names Dr. Roger Tung to Its Board of Directors - bit.ly/2z1JXsJ

Flex Pharma to Report Third Quarter 2017 Results on November 6, 2017 - bit.ly/2z1JXsJ

Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALS - bit.ly/2z1JXsJ

Flex Pharma Reports Third Quarter 2017 Financial Results - bit.ly/2z1JXsJ

Flex Pharma Reports First Quarter 2018 Financial Results: bit.ly/2z1JXsJ